ABOS logo

ACUMEN PHARMACEUTICALS INC

ABOSNASDAQ
🏆 #3833 by market capEarnings Nov 11US Equity
$2.24▼ $0.06 (−2.83%)
After hours · at close
🔔
Track ABOS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.8%
7d▼ 15.7%
14d▼ 22.9%
30d▼ 23.2%
ytd▲ 7.2%
1y▲ 42.4%
🏦Market Cap
$161M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$2.22 – $2.26
52-Week Range
$1.50 – $3.60
Volume
$5.03B
Avg Volume
$5.64B
Shares Outstanding
72.2M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$15M
Last Q Revenue
$4M
P/E Ratio
-1.4
P/S Ratio
0.0x
EPS (TTM)
$-1.45
Dividend Yield
0.00%
Dilution (1yr)
+0.9%

Why Investors Own ABOS

  • ✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 56% gross margin and 4% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABOS logo

ACUMEN PHARMACEUTICALS INC

ABOS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$124M▲ +8.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$116M▲ +34.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.6M▲ +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$23M▲ +$17M YoY
StockOtter · stockotter.space

About ACUMEN PHARMACEUTICALS INC

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy6
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

ACUMEN PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift ABOS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ACUMEN PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.